<DOC>
	<DOCNO>NCT00436566</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin , cyclophosphamide , paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Lapatinib may stop growth tumor cell block enzymes need cell growth . Giving combination chemotherapy together trastuzumab lapatinib surgery may kill tumor cell remain surgery . PURPOSE : This randomized phase II trial study side effect well give doxorubicin together cyclophosphamide follow trastuzumab , paclitaxel , lapatinib work treat patient early-stage HER2-positive breast cancer remove surgery .</brief_summary>
	<brief_title>Doxorubicin Cyclophosphamide Followed By Trastuzumab , Paclitaxel , Lapatinib Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine cardiac safety adjuvant therapy comprise doxorubicin hydrochloride cyclophosphamide follow paclitaxel , trastuzumab ( Herceptin® ) , lapatinib ditosylate patient resect early-stage HER2-positive breast cancer . Secondary - Determine adverse event profile regimen patient . - Determine cumulative incidence cardiac event patient treat regimen . - Determine LVEF patient treat regimen . - Determine disease-free overall survival patient treat regimen . - Compare select quality-of-life ( QOL ) questionnaires patient . - Evaluate QOL patient treat regimen . - Determine cumulative incidence pulmonary event patient treat regimen . Tertiary - Compare Veridex CellSearch system v quantitative reverse transcriptase polymerase chain reaction detect circulate tumor cell . - Determine relationship serum level HER1 HER2 response treatment . - Evaluate cardiac marker ( i.e. , troponin-T , troponin-I , brain natriuretic peptide , creatine kinase MB isoenzyme ) baseline . - Determine association abnormal level cardiac marker incidence cardiac adverse event . - Evaluate pattern 500 metabolite plasma patient treat regimen determine association metabolite patterns/molecular signature cardiotoxicity . - Determine time course molecular signature evaluate whether accurate predictor cardiotoxicity precede evidence cardiotoxicity ( e.g. , change leave ventricular function see echocardiogram MUGA scan ) . - Compare metabolic signature cardiotoxicity know laboratory evidence cardiac damage ( e.g. , troponins brain natriuretic peptide ) term sensitivity specificity . OUTLINE : This randomize , pilot , multicenter study . Patients stratify accord educational level ( less high school v high school GED v formal education beyond high school ) . Patients receive doxorubicin hydrochloride IV cyclophosphamide IV day 1 . Treatment repeat every 2-3 week 4 course . Patients receive paclitaxel IV 60 minute trastuzumab ( Herceptin® ) IV 90 minute day 1 , 8 , 15 oral lapatinib ditosylate day 1-21 . Treatment paclitaxel , trastuzumab , lapatinib repeat every 3 week 4 course . Patients receive trastuzumab IV 30-90 minute day 1 oral lapatinib ditosylate day 1-21 . Treatment trastuzumab lapatinib ditosylate repeat every 3 week 12 course . Patients complete Linear Anologue Self Assessment ( LASA ) Symptoms Distress Scale ( SDS ) questionnaire , include fatigue , diarrhea , rash assessment , baseline , 2-3 , 5-6 , 18 month treatment , 5 year completion treatment . Patients also randomize 1 2 arm complete additional quality life questionnaire time point . - Arm I : Patients complete EORTC QLQ-C30 EORTC QLQ-BR23 questionnaire . - Arm II : Patients complete FACT-B questionnaire . Blood sample acquire periodically throughout completion study treatment . Samples analyze circulate tumor cell Veridex CellSearch system , quantitative reverse transcriptase polymerase chain reaction , liquid chromatography tandem mass spectrometry , soluble HER1- HER2-receptor concentration , circulate cardiac marker , metabolic marker possible correlation cardiac event . After completion study treatment , patient follow periodically 10 year . PROJECTED ACCRUAL : A total 109 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis earlystage breast cancer HER2 positive immunohistochemistry ( IHC ) ( 3+ ) fluorescent situ hybridization ( FISH ) Ductal carcinoma situ ( DCIS ) component count determination degree IHC stain FISH amplification No locally advance tumor ( i.e. , T4 ) diagnosis , include follow : Tumors fix chest wall Peau d'orange Skin ulceration nodules Clinical inflammatory change ( e.g. , diffuse brawny cutaneous induration erysipeloid edge ) Has undergone mastectomy lumpectomy axillary node sentinel node dissection within past 84 day Patients undergone mastectomy must meet following criterion : No evidence gross microscopic tumor ( i.e. , invasive DCIS ) surgical resection margin note final surgery pathology report Patients close margin eligible Radiation therapy require 4 positive lymph node must start completion chemotherapy Patients undergone lumpectomy axillary node sentinel node dissection must meet following criterion : No evidence invasive cancer DCIS surgical resection margin No gross residual adenopathy Planning undergo radiation therapy breast without regional lymphatics completion chemotherapy No active hepatic biliary disease Patients liver metastasis , stable chronic liver disease , Gilbert 's syndrome , asymptomatic gallstone eligible Hormone receptor status : Estrogen receptor progesterone receptor status know PATIENT CHARACTERISTICS : Male female Menopausal status specify ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10.0 g/dL Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Creatinine normal OR creatinine clearance ≥ 60 mL/min LVEF ≥ 50 % MUGA scan echocardiogram Able complete questionnaire ( ) assistance Able willing provide blood tissue sample No known sensitivity benzyl alcohol No sensory neuropathy ≥ grade 2 No active cardiac disease , include follow : Myocardial infarction within past 6 month Prior concurrent congestive heart failure Prior concurrent arrhythmia cardiac valvular disease require medication clinically significant Uncontrolled hypertension , define diastolic blood pressure ( BP ) &gt; 100 mm Hg systolic BP &gt; 200 mm Hg 2 separate occasion ≥ 14 day apart Clinically significant pericardial effusion Prior concurrent uncontrolled symptomatic angina Other cardiac condition , opinion treat physician , would put patient hazardous risk No history allergic reaction attribute compound similar chemical biologic composition lapatinib ditosylate No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Psychiatric illness social situation would preclude study compliance Able swallow retain oral medication No history gastrointestinal ( GI ) disease result inability take oral medication , include follow : Malabsorption syndrome Requirement IV alimentation Prior surgical procedure affect absorption Uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease ulcerative colitis ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy , radiation therapy , immunotherapy , biotherapy breast cancer No primary breast radiation therapy part breastconserving treatment No prior anthracycline taxane therapy malignancy No prior epidermal growth factor receptortargeting therapy ( e.g. , gefitinib , cetuximab , erlotinib hydrochloride , rituximab , trastuzumab [ Herceptin® ] , lapatinib ditosylate , panitumumab , nimotuzumab ) At least 14 day since prior concurrent CYP3A4 inducer , include follow : Rifamycinclass antibiotic ( e.g. , rifampin , rifabutin , rifapentine ) Anticonvulsants ( e.g. , phenytoin , carbamazepine , barbiturates [ e.g. , phenobarbital ] ) Antiretrovirals ( e.g. , efavirenz nevirapine ) Glucocorticoids ( e.g. , oral cortisone , hydrocortisone , prednisone , methylprednisolone , dexamethasone ) Daily oral dexamethasone ≤ 1.5 mg ( equivalent ) allow Modafinil Hypericum perforatum ( St. John 's wort ) At least 7 day since prior concurrent CYP3A4 inhibitor , include follow : Antibiotics ( e.g. , clarithromycin , erythromycin , troleandomycin ) Antifungals ( e.g. , itraconazole , ketoconazole , fluconazole [ &gt; 150 mg daily ] , voriconazole ) Antiretrovirals protease inhibitor ( e.g. , delaviridine , nelfinavir , amprenavir , ritonavir , indinavir , saquinavir , lopinavir ) Calcium channel blocker ( e.g. , verapamil diltiazem ) Antidepressants ( e.g. , nefazodone fluvoxamine ) Gastrointestinal agent ( e.g. , cimetidine aprepitant ) Grapefruit grapefruit juice At least 6 month since prior concurrent amiodarone No herbal alternative medicine supplement ≥ 14 day , , 30 day completion study treatment No concurrent hormonal agent ( e.g. , birth control pill , ovarian hormonal replacement therapy , raloxifene ) Adjuvant hormonal agent ( e.g. , tamoxifen , aromatase inhibitor ) allow completion chemotherapy part treatment breast cancer No concurrent antiretroviral therapy HIVpositive patient No concurrent digitalis betablockers congestive heart failure No concurrent arrhythmia angina pectoris medication No concurrent investigational agent anticancer therapy , include cytotoxic agent immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>cardiac toxicity</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>